Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Carla L. Alves"'
Autor:
Leena Karimi, Carla L. Alves, Mikkel G. Terp, Martina Tuttolomondo, Neil Portman, Sidse Ehmsen, Lene E. Johansen, Martin Bak, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Cancer Communications, Vol 43, Iss 6, Pp 720-725 (2023)
Externí odkaz:
https://doaj.org/article/6e1f64b76d404c68a6d355c985622504
Autor:
Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen, Martina Tuttolomondo, Mikkel G. Terp, Lene E. Johansen, Henriette Vever, Luna V. A. Hoeg, Daniel Elias, Martin Bak, Henrik J. Ditzel
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-16 (2022)
Abstract Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor-positive (ER+) breast cancer. Understanding the resistance mech
Externí odkaz:
https://doaj.org/article/9f1ef5ffbaa6447d89604c247e5ea621
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and
Externí odkaz:
https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
Autor:
Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Abstract Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need
Externí odkaz:
https://doaj.org/article/7cbcb174cf144b08807aab383e525e6b
Autor:
Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic
Externí odkaz:
https://doaj.org/article/c7b5ad6a5a674cfcb8ece9f12b5c68d6
Autor:
Carla L. Alves, Henrik J. Ditzel
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 5, p 4522 (2023)
The frequent activation of the PI3K/AKT/mTOR pathway and its crucial role in estrogen receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a highly attractive therapeutic target in this breast cancer subtype. Consequent
Externí odkaz:
https://doaj.org/article/871e1ca628e54014a2045f7e09e9b632
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 17, p 10053 (2022)
Triple-negative breast cancer (TNBC) is a heterogeneous disease that accounts for 10–15% of all breast cancer cases. Within TNBC, the treatment of basal B is the most challenging due to its highly invasive potential, and thus treatments to suppress
Externí odkaz:
https://doaj.org/article/2db0d0171d1f44699bff5f131e24bde9
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background Endocrine resistance in estrogen receptor-positive (ER+) breast cancer is a major clinical problem and is associated with accelerated cancer cell growth, increased motility and acquisition of mesenchymal characteristics. However,
Externí odkaz:
https://doaj.org/article/6d96047b28244a8a92ff2f513e4018a9
Publikováno v:
Cancers, Vol 13, Iss 21, p 5397 (2021)
The introduction of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) has revolutionized the treatment landscape for patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) and has become the new standard trea
Externí odkaz:
https://doaj.org/article/e0d512c167784d4ab2aa38eb43b5651e
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30